-
Highlights of ISEH 2025: Preview of China-Japan Joint Workshop on Stem Cells and Cell Therapy
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) will be held in Kumamoto, Japan, from September 24 to 27, 2025. One of the major…
-
Blood Science Update | Unlocking TRAIL’s Potential in Hematologic Malignancies: Mechanisms, Resistance, and Emerging Therapeutic Strategies
Mechanisms of TRAIL-Induced Apoptosis （Blood Science. 7(2):e00221, June 2025.） TRAIL is a type II transmembrane protein that initiates apoptosis by binding to its cognate death receptors DR4 and DR5. This interaction…
-
Blood Science Update | Defining Transplant Indications in Acute Leukemia: The Expanding Role of Measurable Residual Disease
MRD Detection Platforms Several platforms are available for MRD detection, each with distinct advantages and limitations. Multiparameter flow cytometry (MFC) remains widely adopted for its rapid turnaround and applicability to…
-
Blood Science Update | Advancing the Diagnosis and Management of Primary Vitreoretinal Lymphoma: New Insights and Future Perspectives
Diagnostic Approaches （Blood Science. 7(2):e00233, June 2025.） Diagnosing PVRL requires a combination of clinical evaluation, ocular imaging, cytological analysis, and molecular testing. Cytological examination of vitreous samples is the gold standard,…
-
Blood Science Update | TREML2 Enhances Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via Suppression of the ERK Signaling Pathway
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid precursor cells. Cytarabine (Ara-C) remains a cornerstone of induction chemotherapy; however, primary and acquired resistance to Ara-C significantly limits its therapeutic efficacy. Emerging studies have suggested that immune checkpoint and receptor molecules may influence tumor chemosensitivity, yet the role of…
-
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial
Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial…
-
Blood Science Update | Unexpected Poor Prognosis in ZNF618::NUTM1-Positive B-ALL: A Rare Case Defies Clinical Assumptions
ZNF618::NUTM1-rearranged B-cell lymphoblastic leukemia (B-ALL) is recognized as a rare but favorable subtype of pediatric leukemia. However, this new case report published in Blood Science challenges that prognostic certainty, documenting a 3-year-old patient whose disease proved resistant to conventional chemotherapy, multiple CAR-T therapies, and hematopoietic stem cell transplantation. The findings underscore the need to reassess…
Connecting Medical Expertise through Media
